FDA Warns of Increased Risk For Aortic Ruptures With Fluoroquinolone in Certain Patients
A review from the U.S. Food and Drug Administration (FDA) found that fluoroquinolone antibiotics can increase the occurrence of rare but serious events of aortic dissections or ruptures of an aortic aneurysm.
Fluoroquinolones should not be used in patients at increased risk unless there are no other treatment options available. Patients at increased risk include those with a history of blockages or aneurysms of the aorta or other blood vessels, high blood pressure, certain genetic disorders that involve blood vessel changes and the elderly. Read the full FDA alert here.
Keywords: ACC Advocacy, Aortic Rupture, Fluoroquinolones, United States Food and Drug Administration, Aortic Aneurysm
< Back to Listings